Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody

John Devincenzo, Jody Aitken, Lisa Harrison

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

It has not been determined whether respiratory syncytial virus (RSV) fusion protein monoclonal antibody (MAb) (palivizumab) reduces infection or simply ameliorates disease. In a prospective observational study, 27 hospitalized premature infants with RSV who were not receiving MAb were compared with 10 such patients who were receiving MAb. Mean (SEM) RSV loads in the MAb and non-MAb groups were 3.36 (0.59) versus 4.89 (0.27) logPFU/ml (P = .01). Prophylactic palivizumab reduces nasal RSV in premature hospitalized infants.

Original languageEnglish (US)
Pages (from-to)123-126
Number of pages4
JournalJournal of Pediatrics
Volume143
Issue number1
DOIs
StatePublished - Jul 1 2003

Fingerprint

Viral Fusion Proteins
Respiratory Syncytial Viruses
Premature Infants
Monoclonal Antibodies
Nose
Observational Studies
Prospective Studies
Antibodies
Infection
Palivizumab

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody. / Devincenzo, John; Aitken, Jody; Harrison, Lisa.

In: Journal of Pediatrics, Vol. 143, No. 1, 01.07.2003, p. 123-126.

Research output: Contribution to journalArticle

@article{d12131a478ef4fb9b873b85dd46db91a,
title = "Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody",
abstract = "It has not been determined whether respiratory syncytial virus (RSV) fusion protein monoclonal antibody (MAb) (palivizumab) reduces infection or simply ameliorates disease. In a prospective observational study, 27 hospitalized premature infants with RSV who were not receiving MAb were compared with 10 such patients who were receiving MAb. Mean (SEM) RSV loads in the MAb and non-MAb groups were 3.36 (0.59) versus 4.89 (0.27) logPFU/ml (P = .01). Prophylactic palivizumab reduces nasal RSV in premature hospitalized infants.",
author = "John Devincenzo and Jody Aitken and Lisa Harrison",
year = "2003",
month = "7",
day = "1",
doi = "10.1016/S0022-3476(03)00213-0",
language = "English (US)",
volume = "143",
pages = "123--126",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody

AU - Devincenzo, John

AU - Aitken, Jody

AU - Harrison, Lisa

PY - 2003/7/1

Y1 - 2003/7/1

N2 - It has not been determined whether respiratory syncytial virus (RSV) fusion protein monoclonal antibody (MAb) (palivizumab) reduces infection or simply ameliorates disease. In a prospective observational study, 27 hospitalized premature infants with RSV who were not receiving MAb were compared with 10 such patients who were receiving MAb. Mean (SEM) RSV loads in the MAb and non-MAb groups were 3.36 (0.59) versus 4.89 (0.27) logPFU/ml (P = .01). Prophylactic palivizumab reduces nasal RSV in premature hospitalized infants.

AB - It has not been determined whether respiratory syncytial virus (RSV) fusion protein monoclonal antibody (MAb) (palivizumab) reduces infection or simply ameliorates disease. In a prospective observational study, 27 hospitalized premature infants with RSV who were not receiving MAb were compared with 10 such patients who were receiving MAb. Mean (SEM) RSV loads in the MAb and non-MAb groups were 3.36 (0.59) versus 4.89 (0.27) logPFU/ml (P = .01). Prophylactic palivizumab reduces nasal RSV in premature hospitalized infants.

UR - http://www.scopus.com/inward/record.url?scp=0042243531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042243531&partnerID=8YFLogxK

U2 - 10.1016/S0022-3476(03)00213-0

DO - 10.1016/S0022-3476(03)00213-0

M3 - Article

VL - 143

SP - 123

EP - 126

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 1

ER -